NOVEL ANTIANDROGEN ARN-509 IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Shore, Neal D.
Antonarakis, Emmanuel S.
Ryan, Charles J.
Berry, William R.
Liu, Glenn
Higano, Celestia
Maneval, Edna Chow
Bandekar, Rajesh
de Boer, Carla J.
Todd, Mary B.
Yu, Margaret K.
Rathkopf, Dana E.
Smith, Matthew R.
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.1961
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP87-16
引用
收藏
页码：E1090 / E1090
页数：1
相关论文
共 50 条
  • [1] ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC)
    Smith, Matthew Raymond
    Antonarakis, Emmanuel S.
    Ryan, Charles J.
    Berry, William R.
    Shore, Neal
    Liu, Glenn
    Alumkal, Joshi J.
    Higano, Celestia S.
    Maneval, Edna Chow
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [2] Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
    Rathkopf, Dana E.
    Morris, Michael J.
    Fox, Josef J.
    Danila, Daniel C.
    Slovin, Susan F.
    Hager, Jeffrey H.
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Goenen, Mithat
    Fleisher, Martin
    Larson, Steven M.
    Sawyers, Charles L.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) : 3525 - +
  • [3] ARN-509 IS SAFE AND EFFECTIVE IN CASTRATION-RESISTANT PROSTATE CANCER
    不详
    CANCER DISCOVERY, 2013, 3 (10) : 1093 - 1093
  • [4] ARN-509 IN MEN WITH HIGH RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Smith, M. R.
    Antonarakis, E. S.
    Ryan, C. J.
    Berry, W.
    Shore, N. D.
    Liu, G.
    Alumkal, J.
    Higano, C.
    Chow-Maneval, E.
    Rathkopf, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 303 - 303
  • [5] ARN-509 in men with high risk non-metastatic castration-resistant prostate cancer
    Smith, M. R.
    Antonarakis, E. S.
    Ryan, C. J.
    Berry, W. R.
    Shore, N. D.
    Liu, G.
    Alumkal, J. J.
    Higano, C. S.
    Maneval, E. Chow
    Rathkopf, D. E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S695 - S695
  • [6] ARN-509 IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Rathkopf, D.
    Antonarakis, E. S.
    Shore, N. D.
    Tutrone, R.
    Alumkal, J.
    Ryan, C. J.
    Saleh, M.
    Hauke, R.
    Chow-Maneval, E.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 317 - 317
  • [7] ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Maneval, Edna Chow
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
    Clegg, Nicola J.
    Wongvipat, John
    Joseph, James D.
    Tran, Chris
    Ouk, Samedy
    Dilhas, Anna
    Chen, Yu
    Grillot, Kate
    Bischoff, Eric D.
    Cal, Ling
    Aparicio, Anna
    Dorow, Steven
    Arora, Vivek
    Shao, Gang
    Qian, Jing
    Zhao, Hong
    Yang, Guangbin
    Cao, Chunyan
    Sensintaffar, John
    Wasielewska, Teresa
    Herbert, Mark R.
    Bonnefous, Celine
    Darimont, Beatrice
    Scher, Howard I.
    Smith-Jones, Peter
    Klang, Mark
    Smith, Nicholas D.
    De Stanchina, Elisa
    Wu, Nian
    Ouerfelli, Ouathek
    Rix, Peter J.
    Heyman, Richard A.
    Jung, Michael E.
    Sawyers, Charles L.
    Hager, Jeffrey H.
    CANCER RESEARCH, 2012, 72 (06) : 1494 - 1503
  • [9] Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
    Smith, Matthew R.
    Antonarakis, Emmanuel S.
    Ryan, Charles J.
    Berry, William R.
    Shore, Neal D.
    Liu, Glenn
    Alumkal, Joshi J.
    Higano, Celestia S.
    Maneval, Edna Chow
    Bandekar, Rajesh
    de Boer, Carla J.
    Yu, Margaret K.
    Rathkopf, Dana E.
    EUROPEAN UROLOGY, 2016, 70 (06) : 963 - 970
  • [10] Effect of the novel anti-androgen ARN-509 on response and seizure in castration-resistant prostate cancer models
    Hager, J. H.
    Smith, N. D.
    Bischoff, E.
    Jung, M. E.
    Sawyers, C. L.
    Heyman, R. A.
    Rix, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345